Pharmaceuticals
Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress
SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 27, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other ma...
2020-08-27 09:37
10631
Digital International Liver Congress: Alcohol cravings could be reduced by changing gut microbiota, new study reveals
GENEVA, Aug. 27, 2020 /PRNewswire/ -- The importance of gut microbiota in reducing the burden of alcohol-related liver disease and liver cancer has been demonstrated in a novel pilot study presented at The Digital International Liver Congress™ 2020. The study examined whether the transfer of fec...
2020-08-27 06:01
4156
Fosun Pharma Announces 2020 Interim Results
SHANGHAI, Aug. 26, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group inChina, announced its interim results for the year 2020 ("the Reporting Period"). During the Reporting Period： * The revenue ac...
2020-08-26 22:03
14229
CSPC Pharmaceutical Announces 2020 Interim Results
Profit Attributable To Shareholders Increased 23.2% to RMB2,314 Million Declared An Interim Dividend of HK6 Cents Per Share Proposed A Bonus Issue of 3 Bonus Shares For Every 5 Existing Shares Held HONG KONG, Aug. 26, 2020 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC P...
2020-08-26 12:30
8022
RoboPharma Acquired by Capsa Healthcare to Broaden Reach Into New Pharmacy Automation Markets
WAALWIJK, Netherlands, Aug. 26, 2020 /PRNewswire/ -- RoboPharma announced today the company has been acquired by Capsa Healthcare, a worldwide innovator in healthcare delivery solutions for hospitals, senior care settings, and retail pharmacy providers. Becoming an integral segment within Capsa H...
2020-08-26 08:12
2515
Duke-NUS to Join the TriNetX Network
CAMBRIDGE, Massachusetts, Aug. 26, 2020 /PRNewswire/ -- Duke-NUS, the only graduate-entry medical school inSingapore, has joined the TriNetX global research network to increase clinical trial adoption and to facilitate better collaboration with other global healthcare organizations (HCOs). This l...
2020-08-26 08:00
2681
EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics
PROVIDENCE, R.I., Aug. 25, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics ("EVT"), aNew York-based co...
2020-08-25 23:35
3383
AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab
SEATTLE, Aug. 25, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab (PRV-031) for partn...
2020-08-25 22:00
5811
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program - Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet - Data show robust, consistent and durable clinical response across different ...
2020-08-25 21:22
2702
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
- In an oversubscribed round, top-tier investors provide significant financial resources to accelerate clinical development of potentially best-in-class therapies for inflammatory/autoimmune diseases - SAN DIEGO and TAICANG, SUZHOU, China, Aug. 24, 2020 /PRNewswire/ -- Connect Biopharma ("Connec...
2020-08-24 20:00
9206
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 24, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has entered into a strategic collaboration with Vir Biotechnology (Nasdaq: VIR), a clinical-stage immunology...
2020-08-24 19:00
3655
PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
SHANGHAI, Aug. 24, 2020 /PRNewswire/ -- PharmaSources.com, the vertical B2B portal for the pharmaceutical industry, announces the launch of the virtual session CPhI China Top API Exporters & Products on24-28 August 2020, as part of the CPhI & P-MEC China E-Trade Season (August toOctober 2020). ...
2020-08-24 16:58
3344
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors
NORTH BRUNSWICK, N.J., Aug. 24, 2020 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that the first patient has been dosed in a phase1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in c...
2020-08-24 13:13
1550
SDIC leads the investment of Xuanzhu Biopharmaceutical with RMB 800 million, promoting innovation and R&D
HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu Biopharmaceutical, its innovative drug research and development platform, su...
2020-08-24 10:20
10405
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...
2020-08-24 09:14
6631
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020
CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SUZHOU, China, Aug. 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody - BCMA x CD3 (HBM7020) at the Cell engager Summit. HBM7020 was develo...
2020-08-21 21:31
7436
Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)
MUMBAI, India, Aug. 21, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General ofIndia (DCGI) for the launch of Stempeucel® in India. The...
2020-08-21 06:00
9803
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC co...
2020-08-20 20:00
4203
Sihuan Pharmaceutical Introduced Investors for Capital Increase to Accelerate Solid-liquid Double Chamber Infusion Soft Bag Industry
HONG KONG, Aug. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Beijing Ruiye Drugs Manufacture Co., Ltd. ("Beijing Ruiye"), an associate of the Grou...
2020-08-20 19:39
14071
111, Inc. Announces Second Quarter 2020 Unaudited Financial Results
SHANGHAI, Aug. 20, 2020 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a company dedicated to digitally connecting patients with drugs and healthcare services inChina, today announced its unaudited financial results for the second quarter endedJune 30, 2020. Second Quarter 2020...
2020-08-20 16:35
11623
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
6428
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4908
Premium Features, Budget Price: Don't Miss the Fossibot S3 Pro's Dual-Screen AMOLED Debut
2025-01-19 15:00
4400
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4275
TikTok "Refugees" Flock to U.S. Owned Rival, Triller
2025-01-19 03:53
4070